» Articles » PMID: 25934765

Dietary ω-3 Fatty Acids Protect Against Vasculopathy in a Transgenic Mouse Model of Sickle Cell Disease

Overview
Journal Haematologica
Specialty Hematology
Date 2015 May 3
PMID 25934765
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The anemia of sickle cell disease is associated with a severe inflammatory vasculopathy and endothelial dysfunction, which leads to painful and life-threatening clinical complications. Growing evidence supports the anti-inflammatory properties of ω-3 fatty acids in clinical models of endothelial dysfunction. Promising but limited studies show potential therapeutic effects of ω-3 fatty acid supplementation in sickle cell disease. Here, we treated humanized healthy and sickle cell mice for 6 weeks with ω-3 fatty acid diet (fish-oil diet). We found that a ω-3 fatty acid diet: (i) normalizes red cell membrane ω-6/ω-3 ratio; (ii) reduces neutrophil count; (iii) decreases endothelial activation by targeting endothelin-1 and (iv) improves left ventricular outflow tract dimensions. In a hypoxia-reoxygenation model of acute vaso-occlusive crisis, a ω-3 fatty acid diet reduced systemic and local inflammation and protected against sickle cell-related end-organ injury. Using isolated aortas from sickle cell mice exposed to hypoxia-reoxygenation, we demonstrated a direct impact of a ω-3 fatty acid diet on vascular activation, inflammation, and anti-oxidant systems. Our data provide the rationale for ω-3 dietary supplementation as a therapeutic intervention to reduce vascular dysfunction in sickle cell disease.

Citing Articles

A review on disease modifying pharmacologic therapies for sickle cell disease.

Mahadevia H, Ponvilawan B, Madan U, Sharma P, Qasim H, Shrestha A Ann Hematol. 2025; .

PMID: 39828781 DOI: 10.1007/s00277-025-06216-1.


Revolutionizing Cardiovascular Health with Nano Encapsulated Omega-3 Fatty Acids: A Nano-Solution Approach.

Gill R, Al-Badr M, AlGhouti M, Mohamed N, Abou-Saleh H, Rahman M Mar Drugs. 2024; 22(6).

PMID: 38921567 PMC: 11204627. DOI: 10.3390/md22060256.


Management of the Sickle Cell Trait: An Opinion by Expert Panel Members.

Pinto V, De Franceschi L, Gianesin B, Gigante A, Graziadei G, Lombardini L J Clin Med. 2023; 12(10).

PMID: 37240547 PMC: 10219090. DOI: 10.3390/jcm12103441.


Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach.

Maule M, Olivieri B, Guarnieri G, De Franceschi L, Martinelli N, Vaia R J Clin Med. 2023; 12(6).

PMID: 36983294 PMC: 10059265. DOI: 10.3390/jcm12062294.


In Humanized Sickle Cell Mice, Imatinib Protects Against Sickle Cell-Related Injury.

Federti E, Matte A, Recchiuti A, Garello F, Ghigo A, El Nemer W Hemasphere. 2023; 7(3):e848.

PMID: 36874380 PMC: 9977487. DOI: 10.1097/HS9.0000000000000848.


References
1.
Rybicki A, Benjamin L . Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood. 1998; 92(7):2594-6. View

2.
Chen S, Park S, Kim M, Brown K, DAgati V, Lee H . Human heat shock protein 27 overexpressing mice are protected against hepatic ischemia and reperfusion injury. Transplantation. 2009; 87(10):1478-87. PMC: 2726263. DOI: 10.1097/TP.0b013e3181a3c691. View

3.
De Caterina R . n-3 fatty acids in cardiovascular disease. N Engl J Med. 2011; 364(25):2439-50. DOI: 10.1056/NEJMra1008153. View

4.
De Franceschi L, Malpeli G, Scarpa A, Janin A, Muchitsch E, Roncada P . Protective effects of S-nitrosoalbumin on lung injury induced by hypoxia-reoxygenation in mouse model of sickle cell disease. Am J Physiol Lung Cell Mol Physiol. 2006; 291(3):L457-65. DOI: 10.1152/ajplung.00462.2005. View

5.
Chihara J, Yamamoto T, Kurachi D, Nakajima S . Soluble ICAM-1 in sputum of patients with bronchial asthma. Lancet. 1994; 343(8905):1108. DOI: 10.1016/s0140-6736(94)90224-0. View